download
print
% Change:
Volume:
52-Week High:
52-Week Low:

EVENTS & PRESENTATIONS

Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call

Past Events ›

Needham 24th Annual Virtual Healthcare Conference

Past Events ›

Alnylam 2025 R&D Day

Past Events ›

View all events and presentations ›
container-970 d-flex flex-1

2024 Annual Report

Download

2023 Corporate Responsibility Report

Download

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Quarterly Earnings Presentation - Icon

Q1 2025 Earnings Presentation VIEW PDF ›

10-K - Icon

Latest Form 10-K VIEW PDF ›

10-Q - Icon

Latest Form10-Q VIEW PDF ›

sec-icon

SEC
Filings VIEW All ›

sec-icon

2025 Proxy Statement LEARN MORE ›

View all resources and documents ›

Discover Our Commitment to Patients, Employees, and Our Communities

Corporate Responsibility ›

PRESS RELEASES

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Learn More ›

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

Learn More ›

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Learn More ›

View all press releases ›